Apixaban Dosing for DVT in Patients Already Taking Aspirin

Initial Treatment Phase

The American College of Cardiology recommends starting apixaban at 10 mg orally twice daily for 7 days, regardless of concurrent aspirin use, for patients with DVT 1
The American College of Chest Physicians recommends discontinuing aspirin when initiating therapeutic anticoagulation with apixaban, as aspirin is significantly less effective than anticoagulation for VTE treatment and adds bleeding risk without meaningful benefit 2, 3, 4

The American College of Cardiology recommends reducing apixaban to 5 mg orally twice daily after the initial 7 days, and continuing this dose for at least 6 months total treatment duration 1
The American College of Chest Physicians recommends keeping aspirin discontinued during the therapeutic anticoagulation phase 2, 5

The American College of Chest Physicians recommends considering extended anticoagulation with reduced-dose apixaban 2.5 mg twice daily after completing 6 months of full-dose therapy, if the DVT was unprovoked or associated with persistent risk factors 2, 3, 4, 5
Reduced-dose apixaban is strongly preferred over aspirin for extended VTE prevention, as it reduces recurrent VTE by 46 fewer events per 1,000 patients compared to aspirin 3, 4

The American College of Chest Physicians recommends offering extended-phase anticoagulation for unprovoked DVT or persistent risk factors, such as active cancer or antiphospholipid syndrome 2, 5, 6
The preferred regimen is apixaban 2.5 mg twice daily over full-dose (5 mg twice daily) for extended prevention 2, 3, 4

The American College of Chest Physicians recommends not using aspirin as a substitute for therapeutic anticoagulation during acute DVT treatment, as this significantly increases risk of recurrent VTE 2, 4
The American College of Chest Physicians recommends not continuing aspirin alongside full-dose apixaban during the initial 6-month treatment period, as this increases bleeding risk without proven benefit for VTE 2
The American College of Chest Physicians recommends not using full-dose apixaban (5 mg twice daily) for extended prevention when reduced-dose (2.5 mg twice daily) is available, as the reduced dose provides similar efficacy with 10 fewer bleeding events per 1,000 patients 3, 4

The American College of Chest Physicians recommends reassessing the need for extended anticoagulation at least annually and with any significant change in health status 2, 5, 6
For patients with transient provoked DVT, extended anticoagulation is generally not recommended after completing 3-6 months of treatment 2, 5